Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.

Abstract

A 79 year-old man was treated with Interferon alpha for chronic myelogenous leukemia and developed severe parkinsonism that resolved after Interferon alpha was stopped. Carbidopa-levodopa was associated with early improvement, but discontinuation did not result in worsening of the parkinsonism.

• Authors: Pichaya Sarasombath, Kenneth Sumida, David A Kaku
• Journal: Hawaii medical journal (Hawaii Med J) Vol. 61 Issue 3 Pg. 48, 57 (Mar 2002) ISSN: 0017-8594 [Print] United States
• PMID: 11965836 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Antiparkinson Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Levodopa
• Carbidopa

Topics

• Aged
• Antineoplastic Agents (administration & dosage, adverse effects)
• Antiparkinson Agents (administration & dosage)
• Carbidopa (administration & dosage)
• Humans
• Interferon alpha-2
• Interferon-alpha (administration & dosage, adverse effects)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Levodopa (administration & dosage)
• Male
• Parkinson Disease, Secondary (chemically induced, drug therapy)
• Recombinant Proteins
• Treatment Outcome